Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 2/20 | 0.57 |
| ▸ | PLA2G2A | P14555 | 6/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864512 | 0.89 | TSPO (0.52) | TSPOPLA2G2AMTNR1AMTNR1BHCRTR1 | |
| SCHEMBL27505510 | 0.88 | HTR6 (0.50) | TSPOHCRTR1HCRTR2HTR6FABP4 | |
| SCHEMBL11819992 | 0.87 | HTR6 (0.53) | TSPOHTR6FABP4 | |
| SCHEMBL5508890 | 0.85 | PLA2G2A (0.55) | TSPOPLA2G2AMTNR1AMTNR1BHCRTR1 | |
| SCHEMBL419235 | 0.85 | TSPO (0.77) | TSPO | |
| SCHEMBL5506734 | 0.85 | PLA2G2A (0.50) | TSPOPLA2G2AMTNR1AMTNR1BHCRTR1 | |
| SCHEMBL21696320 | 0.85 | TSPO (0.62) | TSPO | |
| SCHEMBL30106112 | 0.85 | TSPO (0.77) | TSPO | |
| SCHEMBL6693579 | 0.85 | FABP4 (0.44) | TSPOPLA2G2AHCRTR1HCRTR2HTR6 | |
| SCHEMBL6694132 | 0.84 | PLA2G2A (0.46) | TSPOPLA2G2AHTR6FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |